Dying patients gain access to experimental drugs blocked by federal scheduling

What it does

This bill amends the Controlled Substances Act to allow physicians to obtain a special registration from the Attorney General to directly administer Schedule I investigational drugs to terminally ill patients under the existing Federal Right to Try law. Physicians must demonstrate valid DEA registration, compliance with Right to Try requirements, state law authorization, and relevant training; the Attorney General must approve or deny applications within 45 days. Patients and physicians gain access to experimental drugs that have not completed FDA approval but show promise for serious conditions.

Why we flagged it

The bill's operative mechanism is to create a supervised administrative pathway for terminally ill patients to access investigational Schedule I drugs under existing Right to Try law. It is not deregulation (Schedule I status remains; DEA oversight continues) but rather a procedural accommodation within the existing regulatory framework.

What the text implies

• Interim final rule (240 days) bypasses normal notice-and-comment rulemaking, allowing rapid implementation before final rule is issued (2 years later). This accelerates access but reduces public input on enforcement details.
• Supplemental notification for additional drug quantities is 'deemed approved' after 30 days unless Attorney General objects—a soft approval mechanism that shifts burden to government to deny rather than physician to justify.

The full analysis lists 3 implications of this text.

Who stands to gain

Pharmaceutical manufacturers and sponsors (supply agreements for investigational drugs); Physicians (expanded scope of practice, potential revenue from Right to Try treatments)